Clinical Trials

48 enrolled

Nasopharyngeal Carcinoma

NCT06156878 2023-12-05

PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

41 enrolled

Nasopharyngeal Carcinoma

NCT03097939 2023-10-11

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

113 enrolled

Nasopharyngeal Carcinoma

NCT05198479 2023-10-11

SG-AAA-II-01

25 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT05626829 2023-10-06

Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma

18 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT05981157 2023-08-08

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

27 enrolled

Nasopharyngeal Carcinoma

NCT03925090 2023-07-03

Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

150 enrolled

Nasopharyngeal Carcinoma

NCT04072107 2023-06-18

EP-STAR

110 enrolled

Nasopharyngeal Carcinoma

NCT04221516 2023-06-18

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

52 enrolled

Nasopharyngeal Carcinoma

NCT04586088 2023-05-06

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

58 enrolled

Nasopharyngeal Carcinoma

NCT05229315 2023-04-13

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

45 enrolled

Nasopharyngeal Carcinoma

NCT05790200 2023-03-30

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

30 enrolled

Nasopharyngeal Carcinoma

NCT04872582 2023-02-23

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

33 enrolled

Nasopharyngeal Carcinoma

NCT05724355 2023-02-13

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

32 enrolled

Nasopharyngeal Carcinoma

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT05563480 2022-12-01

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

90 enrolled

Nasopharyngeal Carcinoma

NCT05448885 2022-07-08

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

50 enrolled

Nasopharyngeal Carcinoma

NCT05417139 2022-06-14

Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study

43 enrolled

Nasopharyngeal Carcinoma

NCT04978012 2022-06-07

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

48 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT05201859 2022-05-06

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

150 enrolled

Nasopharyngeal Carcinoma

NCT03854838 2022-04-29

IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

25 enrolled

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT04143984 2022-04-29

Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma

146 enrolled

Nasopharyngeal Carcinoma

NCT04921995 2022-04-04

RETICULA-NPC

Nasopharyngeal Carcinoma

NCT05232552 2022-02-10

Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma

37 enrolled

Nasopharyngeal Carcinoma

NCT05177237 2022-01-04

Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma

30 enrolled

Nasopharyngeal Carcinoma

NCT05162872 2021-12-17

Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma

99 enrolled

Nasopharyngeal Carcinoma

NCT05092217 2021-10-25

Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma

80 enrolled

Nasopharyngeal Carcinoma

NCT03668730 2021-08-24

Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma

215 enrolled

Nasopharyngeal Carcinoma

NCT04992988 2021-08-20

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Nasopharyngeal Carcinoma

NCT04955886 2021-07-09

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

14 enrolled

Nasopharyngeal Carcinoma

NCT03904225 2021-06-23

Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis

220 enrolled

Nasopharyngeal Carcinoma

NCT04917770 2021-06-08

The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

28 enrolled

Nasopharyngeal Carcinoma

NCT04769076 2021-02-25

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

NCT02636231 2021-02-03

Endostar for Locally Recurrent Nasopharyngeal Carcinoma

96 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT04627961 2020-11-13

A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

33 enrolled

Nasopharyngeal Carcinoma

NCT04547088 2020-09-14

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

27 enrolled

Nasopharyngeal Carcinoma

NCT04548271 2020-09-14

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

25 enrolled

Nasopharyngeal Carcinoma

NCT04534855 2020-09-01

A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation

Nasopharyngeal Carcinoma

NCT03648697 2020-08-11

EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC

20 enrolled

Nasopharyngeal Carcinoma

NCT04447612 2020-06-25

Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

118 enrolled

Nasopharyngeal Carcinoma

NCT04421469 2020-06-09

Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

39 enrolled

Nasopharyngeal Carcinoma

NCT04319471 2020-03-24

Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

70 enrolled

Nasopharyngeal Carcinoma

NCT03923842 2020-02-17

Dern

45 enrolled

Nasopharyngeal Carcinoma

NCT04220528 2020-01-07

Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC

129 enrolled

Nasopharyngeal Carcinoma

NCT03020329 2019-08-07

Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

37 enrolled

Nasopharyngeal Carcinoma

NCT03932266 2019-04-30

Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

73 enrolled

Nasopharyngeal Carcinoma

NCT03778008 2018-12-27

Recombinant Bovine Basic Fibroblast Growth Factor for the Treatment of Radiation Induced Oral Mucositis

90 enrolled

Nasopharyngeal Carcinoma, Stomatitis

NCT03557112 2018-11-02

By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC

180 enrolled

Nasopharyngeal Carcinoma

NCT03666221 2018-09-11

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

67 enrolled